293 related articles for article (PubMed ID: 28330852)
21. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
22. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
Brown RJ; Meehan CA; Cochran E; Rother KI; Kleiner DE; Walter M; Gorden P
J Clin Endocrinol Metab; 2017 May; 102(5):1511-1519. PubMed ID: 28324110
[TBL] [Abstract][Full Text] [Related]
23. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
[TBL] [Abstract][Full Text] [Related]
24. Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis.
Kalavalapalli S; Bril F; Koelmel JP; Abdo K; Guingab J; Andrews P; Li WY; Jose D; Yost RA; Frye RF; Garrett TJ; Cusi K; Sunny NE
Am J Physiol Endocrinol Metab; 2018 Aug; 315(2):E163-E173. PubMed ID: 29634314
[TBL] [Abstract][Full Text] [Related]
25. Acetyl-L-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease.
Kathirvel E; Morgan K; French SW; Morgan TR
Nutr Res; 2013 Nov; 33(11):932-41. PubMed ID: 24176233
[TBL] [Abstract][Full Text] [Related]
26. Membrane-bound
Abulizi A; Vatner DF; Ye Z; Wang Y; Camporez JP; Zhang D; Kahn M; Lyu K; Sirwi A; Cline GW; Hussain MM; Aspichueta P; Samuel VT; Shulman GI
J Lipid Res; 2020 Dec; 61(12):1565-1576. PubMed ID: 32907986
[TBL] [Abstract][Full Text] [Related]
27. Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease.
Sunny NE; Kalavalapalli S; Bril F; Garrett TJ; Nautiyal M; Mathew JT; Williams CM; Cusi K
Am J Physiol Endocrinol Metab; 2015 Aug; 309(4):E311-9. PubMed ID: 26058864
[TBL] [Abstract][Full Text] [Related]
28. Metabolic phenotype and adipose and liver features in a high-fat Western diet-induced mouse model of obesity-linked NAFLD.
Luo Y; Burrington CM; Graff EC; Zhang J; Judd RL; Suksaranjit P; Kaewpoowat Q; Davenport SK; O'Neill AM; Greene MW
Am J Physiol Endocrinol Metab; 2016 Mar; 310(6):E418-39. PubMed ID: 26670487
[TBL] [Abstract][Full Text] [Related]
29. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
Sanyal AJ; Campbell-Sargent C; Mirshahi F; Rizzo WB; Contos MJ; Sterling RK; Luketic VA; Shiffman ML; Clore JN
Gastroenterology; 2001 Apr; 120(5):1183-92. PubMed ID: 11266382
[TBL] [Abstract][Full Text] [Related]
30. The UCP2 -866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis.
Fares R; Petta S; Lombardi R; Grimaudo S; Dongiovanni P; Pipitone R; Rametta R; Fracanzani AL; Mozzi E; Craxì A; Fargion S; Sesti G; Valenti L
Liver Int; 2015 May; 35(5):1574-80. PubMed ID: 25351290
[TBL] [Abstract][Full Text] [Related]
31. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.
Honda Y; Imajo K; Kato T; Kessoku T; Ogawa Y; Tomeno W; Kato S; Mawatari H; Fujita K; Yoneda M; Saito S; Nakajima A
PLoS One; 2016; 11(1):e0146337. PubMed ID: 26731267
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.
Gangarapu V; Ince AT; Baysal B; Kayar Y; Kılıç U; Gök Ö; Uysal Ö; Şenturk H
Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):840-5. PubMed ID: 26043290
[TBL] [Abstract][Full Text] [Related]
33. Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression.
Abd El-Haleim EA; Bahgat AK; Saleh S
World J Gastroenterol; 2016 Mar; 22(10):2931-48. PubMed ID: 26973390
[TBL] [Abstract][Full Text] [Related]
34. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.
Araujo-Vilar D; Sánchez-Iglesias S; Guillín-Amarelle C; Castro A; Lage M; Pazos M; Rial JM; Blasco J; Guillén-Navarro E; Domingo-Jiménez R; del Campo MR; González-Méndez B; Casanueva FF
Endocrine; 2015 May; 49(1):139-47. PubMed ID: 25367549
[TBL] [Abstract][Full Text] [Related]
35. Biochemical parameters response to weight loss in patients with non-alcoholic steatohepatitis.
Abd El-Kader SM; Al-Shreef FM; Al-Jiffri OH
Afr Health Sci; 2016 Mar; 16(1):242-9. PubMed ID: 27358638
[TBL] [Abstract][Full Text] [Related]
36. Oral Administration of
Mizrahi M; Ben Ya'acov A; Adar T; Levy Sklair M; Gaska S; Ilan Y
J Med Food; 2019 Dec; 22(12):1189-1198. PubMed ID: 31634046
[TBL] [Abstract][Full Text] [Related]
37. Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue.
Yoneda M; Iwasaki T; Fujita K; Kirikoshi H; Inamori M; Nozaki Y; Maeyama S; Wada K; Saito S; Terauchi Y; Nakajima A
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S15-21. PubMed ID: 17331160
[TBL] [Abstract][Full Text] [Related]
38. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.
Musso G; Cassader M; De Michieli F; Rosina F; Orlandi F; Gambino R
Hepatology; 2012 Sep; 56(3):933-42. PubMed ID: 22684858
[TBL] [Abstract][Full Text] [Related]
39. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy.
Park JY; Chong AY; Cochran EK; Kleiner DE; Haller MJ; Schatz DA; Gorden P
J Clin Endocrinol Metab; 2008 Jan; 93(1):26-31. PubMed ID: 17940115
[TBL] [Abstract][Full Text] [Related]
40. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
